Crossmark

A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

Crossref DOI link: https://doi.org/10.1186/s13045-016-0379-6

Published Online: 2017-01-03

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Erhao

Xu, Hanmei
Funding

Funding for this research was provided by:

Ministry of Science and Technology of the People's Republic of China (No. SKLNMBZ201403)

Ministry of Science and Technology of the People's Republic of China (No. 2012ZX09103301-004)

Ministry of Science and Technology of the People's Republic of China (No. 2014ZX09508007)